Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2014 09:15 ET | Source: Repros Therapeutics Inc.

Repros Gives Update on Androxal(R) With Respect to Recent FDA Advisory Panel Outcome and Announces Upcoming Presentation at Biocentury

THE WOODLANDS, Texas, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the conclusions of the FDA Advisory Panel that met on Wednesday, September...
August 27, 2014 20:10 ET | Source: Repros Therapeutics Inc.

Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of Secondary Hypogonadism

23.8% of Topical T subjects below 10 million sperm/mL at end of study versus 2.3% and 2.4% respectively for Androxal® and placebo ITT (Androxal® vs. Topical T, p = 0.0031) 33.3%...
August 11, 2014 09:15 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports Second Quarter 2014 Financial Results

THE WOODLANDS, Texas, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2014. Financial Results...
July 16, 2014 09:20 ET | Source: Repros Therapeutics Inc.

FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel and Placebo

Schedule for study completion remains unaffected Company anticipates submission of NDA by year end 2014 THE WOODLANDS, Texas, July 16, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics...
May 13, 2014 10:15 ET | Source: Repros Therapeutics Inc.

Repros Fully Enrolls Second Previously Announced Head to Head Study of Androxal(R) Versus the Leading Topical Testosterone Gel

Company expects topline results by Q4 2014 Study designed to allow comparison of performance of Androxal® to testosterone replacement in restoring and maintaining normal testicular...
May 12, 2014 09:15 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports First Quarter 2014 Financial Results

THE WOODLANDS, Texas, May 12, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2014. Financial Results...
April 30, 2014 16:01 ET | Source: Repros Therapeutics Inc.

FDA Recommends Sperm Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel

Co-primary endpoints of better maintenance of normal sperm concentration and smaller decline in sperm concentration, both compared to topical gel Company believes the timelines for study...
April 14, 2014 09:44 ET | Source: Repros Therapeutics Inc.

Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel

Company expects topline results by October 2014 Studies designed to compare performance of Androxal to testosterone replacement in restoring and maintaining normal testicular function...
March 17, 2014 09:20 ET | Source: Repros Therapeutics Inc.

Repros Allowed to Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex(R) in the Treatment of Uterine Fibroids and Endometriosis

THE WOODLANDS, Texas, March 17, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported it has received guidance from the FDA indicating that Repros may proceed to conduct...
March 13, 2014 09:15 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2013 Financial Results

THE WOODLANDS, Texas, March 13, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31,...